University of Manchester

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

Retrieved on: 
Tuesday, February 21, 2023
DSM-IV codes, Royal Manchester Children's Hospital, AML, PRES, CH50, Thrombocytopenia, Hope, HSCT, Viremia, LTB4, Diagnosis, Leukotriene B4, NHS foundation trust, Thrombotic microangiopathy, Maintenance, GVHD, Division, Hematopoietic stem cell transplantation, Patient, Hospital, Clinical trial, Inflammation, Center for International Blood and Marrow Transplant Research, TMA, University, Research, Therapy, Male, Hypertension, TCA, Death, University of Manchester, Thiotepa, End organ damage, Manchester University NHS Foundation Trust, Cytomegalovirus, System, Transplant, Society, Syndrome, Hot game, Rosenthal, CMV, Pharmaceutical industry, Dentistry, Pediatrics

The case study, Clinical Response to Nomacopan in the Pediatric HSCT-TMA Setting, was presented on Thursday February 16, at 5:45 pm ET at the Transplantation & Cellular Therapy Tandem Meetings in Orlando, Florida.

Key Points: 
  • The case study, Clinical Response to Nomacopan in the Pediatric HSCT-TMA Setting, was presented on Thursday February 16, at 5:45 pm ET at the Transplantation & Cellular Therapy Tandem Meetings in Orlando, Florida.
  • The patient received 7 granulocyte infusions peri-transplant as part of an experimental protocol to augment the graft-versus-leukemia effect.
  • His immediate post-transplant course was complicated by engraftment syndrome, acute gut graft-versus-host disease (GVHD) grade 3 and cytomegalovirus (CMV) viraemia.
  • Nomacopan was stopped for 3 days and restarted after the diagnosis was deemed to be unrelated to nomacopan treatment.

AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023

Retrieved on: 
Thursday, February 9, 2023
Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Gaucher's disease, Safety, Clinical trial, University, MPS, Cystinosis, CNS, HSC, University of Manchester, University of California, San Diego, AVRO, Gaucher, Hunter syndrome, Disease, MPS II, Central nervous system, DSM-IV codes, Pharmaceutical industry, Medical device

The company also announced that data from the fully enrolled, collaborator-sponsored Phase 1/2 clinical trial in cystinosis will be presented at the conference.

Key Points: 
  • The company also announced that data from the fully enrolled, collaborator-sponsored Phase 1/2 clinical trial in cystinosis will be presented at the conference.
  • The company’s planned activities are listed below and the full preliminary program is available online on the WORLDSymposium ™ website.
  • Stuart Ellison, Ph.D., University of Manchester, UK, will present murine data for a central nervous system (CNS)-targeted HSC gene therapy and plans for a Phase 1/2 clinical trial in MPS II or Hunter syndrome.
  • Sustained improvement of clinical CNS and somatic features of GD3 after HSC gene therapy: A first-in-world report
    Aimee Donald, M.D., Ph.D., University of Manchester, UK, will present clinical data from the first pediatric GD3 patient dosed with investigational AVR-RD-02.

Genesis Research Strengthens Board of Directors with Appointments of Professor Carole Longson MBE and Dr. S. Yin Ho, M.D.,M.B.A.

Retrieved on: 
Tuesday, January 17, 2023
Real-World Evidence, NICE, Knowledge, Research, University of Manchester, RWE, GHO, Software, Appointment, Software as a service, Doctor of Philosophy, Health technology assessment, Information technology, M.B.A, Management, Pharmaceutical industry

Genesis Research Strengthens Board of Directors with Appointments of Professor Carole Longson MBE and Dr. S. Yin Ho, M.D.,M.B.A.

Key Points: 
  • Genesis Research Strengthens Board of Directors with Appointments of Professor Carole Longson MBE and Dr. S. Yin Ho, M.D.,M.B.A.
  • HOBOKEN, NJ, 17 January 2023 - Genesis Research (“Genesis” or “the Company”), a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has announced the appointment of Professor Carole Longson MBE and Dr. S. Yin Ho, M.D., M.B.A. to the Board of Directors.
  • Professor Carole Longson MBE is a renowned leader in health technology assessment with over 20 years of experience and considerable achievements in research, public and private sectors.
  • Additionally, Carole holds several Non-Executive Director and advisory roles and is an honorary Professor of Health Technology Assessment at Manchester University.

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

Retrieved on: 
Monday, January 9, 2023
IND, AGN, Brain, Element, University, Merck, Idiopathic pulmonary fibrosis, CSE, P2X3, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, FDA, Respiratory Medicine, Idiopathic disease, University of Manchester, Merck & Co., Patient, U.S. FDA, Food, Manchester University NHS Foundation Trust, Chronic cough, Drug discovery, NHS foundation trust, Cough, Acquisition, NMDA, USD, IPF, Ifenprodil, Pharmaceutical industry, Gefapixant, Algernon

Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough.

Key Points: 
  • Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough.
  • Patients with IPF are usually excluded from trials in refractory chronic cough, and cough in this population is regarded as extremely difficult to treat.
  • While the Company originally planned to focus on IPF in a Phase 2b study, Algernon has now decided to pursue a chronic cough study first, and to delay planning its IPF Phase 2b study for Ifenprodil until a later date.
  • At the time, Gefapixant had interim data from a Phase 2b dose-escalation study in refractory chronic cough.

oneZero appoints Stephen Totten as Director of Quantitative Analysis

Retrieved on: 
Wednesday, January 11, 2023
Citadel, Data Analytics Acceleration Library, Website, Portfolio manager, Health Data Insight, EVP, UniCredit, Morgan Stanley, Data source, Citadel LLC, University of Manchester, EFX, PTF, Mathematics, Engineering, Quantitative analysis, University, Ecosystem, Postgraduate certificate, Birkbeck, University of London, Strategic planning, Macro, Columbia University, Master of Science, Partnership, Risk management, Financial services, Finance, FX

BOSTON, Jan. 11, 2023 /PRNewswire/ -- oneZero, a global leader in multi-asset enterprise trading technology solutions, today announced the appointment of Stephen Totten as Director of Quantitative Analysis. Steve will be responsible for further advancing oneZero's heavy investments in analytics, focusing on solutions for institutional brokers, regional banks, asset managers, PTF's and their EcoSystem Liquidity Partners.

Key Points: 
  • BOSTON, Jan. 11, 2023 /PRNewswire/ -- oneZero, a global leader in multi-asset enterprise trading technology solutions, today announced the appointment of Stephen Totten as Director of Quantitative Analysis.
  • oneZero analytics enable oneZero clients to optimize their use of the oneZero EcoSystem for market access, customer pricing to ensure they meet objectives for serving their client franchise, and risk management strategies to efficiently capture the maximum value from their franchise while staying within their risk tolerances.
  • To this end, oneZero actively works with clients to analyze the results and finds ways to make their business more efficient.
  • Phil Weisberg, EVP of Strategic Planning and Partnerships at oneZero commented: "We are thrilled that Steve has joined us at oneZero.

oneZero appoints Stephen Totten as Director of Quantitative Analysis

Retrieved on: 
Wednesday, January 11, 2023
Citadel, Data Analytics Acceleration Library, Website, Portfolio manager, Health Data Insight, EVP, UniCredit, Morgan Stanley, Data source, Citadel LLC, University of Manchester, EFX, PTF, Mathematics, Engineering, Quantitative analysis, University, Ecosystem, Postgraduate certificate, Birkbeck, University of London, Strategic planning, Macro, Columbia University, Master of Science, Partnership, Risk management, Financial services, Finance, FX

BOSTON, Jan. 11, 2023 /PRNewswire/ -- oneZero, a global leader in multi-asset enterprise trading technology solutions, today announced the appointment of Stephen Totten as Director of Quantitative Analysis. Steve will be responsible for further advancing oneZero's heavy investments in analytics, focusing on solutions for institutional brokers, regional banks, asset managers, PTF's and their EcoSystem Liquidity Partners.

Key Points: 
  • BOSTON, Jan. 11, 2023 /PRNewswire/ -- oneZero, a global leader in multi-asset enterprise trading technology solutions, today announced the appointment of Stephen Totten as Director of Quantitative Analysis.
  • oneZero analytics enable oneZero clients to optimize their use of the oneZero EcoSystem for market access, customer pricing to ensure they meet objectives for serving their client franchise, and risk management strategies to efficiently capture the maximum value from their franchise while staying within their risk tolerances.
  • To this end, oneZero actively works with clients to analyze the results and finds ways to make their business more efficient.
  • Phil Weisberg, EVP of Strategic Planning and Partnerships at oneZero commented: "We are thrilled that Steve has joined us at oneZero.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
Monday, December 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
Monday, December 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

Breast Cancer Detection Using a Blood Test: Syantra to Present Early Data from the International Identify Breast Cancer (IDBC) Study at the 13th European Breast Cancer Conference

Retrieved on: 
Tuesday, November 8, 2022
Wythenshawe Hospital, Breast cancer, Breast, Oncology nursing, Cancer, University of Manchester, AB, Manchester University NHS Foundation Trust, Doctor of Philosophy, Conference, NHS foundation trust, Woman, Multimedia, Medical imaging

Our results will contribute to the field's understanding of how whole blood analysis can be applied in cancer detection and treatment," said Kristina Rinker, PhD.

Key Points: 
  • Our results will contribute to the field's understanding of how whole blood analysis can be applied in cancer detection and treatment," said Kristina Rinker, PhD.
  • "We are looking forward to discussing latest results and engaging with stakeholders advancing cancer detection and treatment."
  • We are excited to share data, which supports the role of the blood test in complementing current imaging approaches for breast cancer detection."
  • Its flagship product, Syantra DXTM Breast Cancer, is a minimally invasive and high-performance blood test for the detection of breast cancer.

Breast Cancer Detection Using a Blood Test: Syantra to Present Early Data from the International Identify Breast Cancer (IDBC) Study at the 13th European Breast Cancer Conference

Retrieved on: 
Tuesday, November 8, 2022
Wythenshawe Hospital, Breast cancer, Breast, Oncology nursing, Cancer, University of Manchester, AB, Manchester University NHS Foundation Trust, Doctor of Philosophy, Conference, NHS foundation trust, Woman, Medical imaging

Our results will contribute to the field's understanding of how whole blood analysis can be applied in cancer detection and treatment," said Kristina Rinker, PhD.

Key Points: 
  • Our results will contribute to the field's understanding of how whole blood analysis can be applied in cancer detection and treatment," said Kristina Rinker, PhD.
  • "We are looking forward to discussing latest results and engaging with stakeholders advancing cancer detection and treatment."
  • We are excited to share data, which supports the role of the blood test in complementing current imaging approaches for breast cancer detection."
  • Its flagship product, Syantra DXTM Breast Cancer, is a minimally invasive and high-performance blood test for the detection of breast cancer.